Published 8 days ago • loading... • Updated 8 days ago

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Summary by Inside Ottawa Valley

Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab

8 Articles

All

Left

Center

Right

NiagaraFallsReview.ca

+7 Reposted by 7 other sources

Lean Left

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab

8 days ago·Niagara Falls, Canada

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year